Life Sciences

  • April 27, 2026

    DOJ Says Wash. 340B Drug Law Is Preempted In Novartis Suit

    The U.S. Department of Justice waded into a dispute between pharmaceutical giants and the state of Washington on Monday, arguing that federal law preempts a new state law that expands discounts that drugmakers must provide under the federal 340B Drug Pricing Program.

  • April 27, 2026

    High Court Appears Split In Monsanto Roundup Appeal

    Monsanto's efforts to stem the tide of thousands of lawsuits over its blockbuster weedkiller Roundup seemed to find a mixed audience with the U.S. Supreme Court justices Monday as they debated the benefits of national labeling standards with how regulators stay on top of changing science.

  • April 27, 2026

    Moderna Hit With Suit Over CureVac COVID Patents

    BioNTech subsidiary CureVac has launched a new patent infringement suit against Moderna, claiming its COVID-19 vaccine infringed a handful of patents, saying the Massachusetts-based company "exploited" its messenger RNA technology.

  • April 27, 2026

    Attys, Advocates Call DOJ Pot Rule Historic Shift For Feds

    Legal strategies are evolving quickly in the wake of last week's "historic" rescheduling of state-legal medical cannabis, as a group of attorneys and advocates gathered Monday to evaluate the trade-offs of dispensaries now being able to register like pharmacies with the feds and the potential effect on industry investments and trade.

  • April 27, 2026

    IQVIA Accuses Ex-Execs, Syneos Of Poaching $180M Client

    IQVIA Holdings Inc. is accusing former executives of defecting to a competitor in the clinical research organization industry and initiating a corporate raid that resulted in the loss of one customer worth at least $180 million, according to a lawsuit filed in North Carolina Business Court.

  • April 27, 2026

    4 Firms Build Astorg's $1.1B Microbiology Biz Buy

    Life sciences company Thermo Fisher Scientific Inc. on Monday announced plans to sell its microbiology business to European private equity firm Astorg in an over $1.1 billion deal steered by four law firms.

  • April 27, 2026

    3rd Circ. Panel Once Again Backs Talc Co. Whittaker's Ch. 11

    The Third Circuit on Monday upheld its decision that Whittaker Clark & Daniels was authorized to file for Chapter 11 and certain claims against the defunct talc supplier's corporate successor belong to the debtor, not personal injury claimants.

  • April 27, 2026

    Bioscience Co. Allegedly Hid Volatility Risks From Investors

    A company purportedly focused on using traditional Chinese medicine to treat conditions including autism spectrum disorder faces a proposed investor class action alleging it downplayed the risk it would be probed in connection with unusual volatility affecting the market for its shares.

  • April 27, 2026

    McCarter & English Plans New Waterfront Home In Boston

    New Jersey-based McCarter & English LLP has chosen a new home for its Boston office, opting for a location in the middle of the city's downtown waterfront district, the firm has announced.

  • April 27, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court this past week tackled a fresh mix of deal litigation, procedural disputes and fiduciary duty claims, with several rulings and filings underscoring the court's continued focus on contractual precision, forum enforcement and the limits of stockholder challenges.

  • April 27, 2026

    What To Watch As Justices Take On 'Skinny Label' Case

    The U.S. Supreme Court will hear arguments Wednesday on whether to permit a patent suit over a generic heart drug using a so-called skinny label, a case with ramifications for the drug industry that could shape patent disputes more broadly and other legal areas. Here's what to watch for.

  • April 27, 2026

    Ropes & Gray, Cooley Lead Lilly's $2.3B Cancer Drug Buy

    Eli Lilly and Co. said Monday it will acquire privately held Ajax Therapeutics in a deal worth up to $2.3 billion, as the drugmaker looks to expand its pipeline of treatments for blood cancers.

  • April 27, 2026

    US, Indian Firms Guide $11.75B Sun Pharma-Organon Deal

    Indian pharmaceutical giant Sun Pharmaceutical Industries Ltd. has agreed to acquire New Jersey-based Organon & Co. in an all-cash deal valued at $11.75 billion, with each side of the transaction having representation from one U.S. and one Indian law firm.

  • April 24, 2026

    Up Last At High Court: TPS, Geofence, Skinny Labels

    The U.S. Supreme Court will close out its oral argument portion of the 2025 October term by hearing a panoply of disputes over the constitutionality of geofence warrants, the existence of aiding and abetting torture claims, and the rescission of temporary protected status for hundreds of thousands of immigrants.

  • April 24, 2026

    Natera Tells Justices CareDx Made Up Circ. Split In Petition

    Natera asked the U.S. Supreme Court to reject a petition from rival CareDx asking it to review a Third Circuit decision that erased a $45 million jury verdict stemming from CareDx's false advertising claims, saying Friday the circuit split that CareDx claims exists is "imagined."

  • April 24, 2026

    NY Court Pauses $100M Saudi Arabia Pharma Award Suit

    A New York federal judge has paused litigation filed by a Qatari pharmaceutical distributor and its chairman aimed at enforcing a nearly $100 million arbitral award against Saudi Arabia while a hearing is conducted in the kingdom's set-aside petition in England next week.

  • April 24, 2026

    What's At Stake As High Court Hears Roundup Appeal

    With a $7.25 billion deal potentially at stake, Monsanto heads to the U.S. Supreme Court on Monday in its closely watched appeal of a $1.25 million jury verdict awarded to a Missouri man who claimed that Roundup weed killer caused his cancer.

  • April 24, 2026

    Danaher Execs Face Investor Suit Over Post-COVID Outlook

    Danaher Corp. executives are facing a proposed securities class action in Delaware federal court alleging they profited while misleading stockholders about the slowing sales of its diagnostics and bioprocessing products.

  • April 24, 2026

    Merck's $6.7B Terns Deal Clears Regulatory Hurdle

    Merck has cleared a key regulatory hurdle in its plan to acquire clinical stage oncology company Terns Pharmaceuticals Inc. for $6.7 billion, the pharmaceutical giant said Friday. 

  • April 24, 2026

    Pfizer, Dexcel Drop Heart Drug Case Before Bench Trial

    Pfizer and Israeli generic-drug maker Dexcel on Friday agreed to drop a case Pfizer brought to block Dexcel from creating a generic version of the heart medication Vyndamax.

  • April 24, 2026

    Biotechs Clash Over Cancer Drug Discovery In Chancery

    AnaptysBio and Tesaro, alongside Tesaro parent GlaxoSmithKline LLC, sparred Friday in the Delaware Chancery Court over the scope of discovery in the biotechnology firms' contract fight regarding cancer drug Jemperli, with each side accusing the other of trying to tilt the evidentiary record ahead of a fast-approaching trial in July.

  • April 24, 2026

    Taxation With Representation: Gibson Dunn, Paul Weiss

    In this week's Taxation With Representation, Elon Musk's SpaceX strikes a deal with Cursor that could lead to an acquisition of the artificial intelligence startup, building products distributor QXO Inc. buys TopBuild Corp., and Eli Lilly & Co. acquires clinical-stage biotechnology company Kelonia Therapeutics.

  • April 23, 2026

    Latest Squires Order Grants 5 IPRs, Denies 4 On The Merits

    U.S. Patent and Trademark Office Director John Squires granted five America Invents Act patent challenges and denied four others in his latest bulk order making institution decisions with little commentary.

  • April 23, 2026

    Full Fed. Circ. Urged To Rethink Corcept Patent Loss

    Corcept Therapeutics Inc. wants the Federal Circuit to rethink a panel's refusal to revive its suit accusing Teva Pharmaceuticals USA Inc. of patent infringement over its production of a generic version of the drug Korlym, saying the panel improperly relied on a ruling from a 2022 case.

  • April 23, 2026

    FTC Cuts Deal To End Anesthesia Group Rollup Case

    The Federal Trade Commission reached an agreement Thursday to settle its case accusing U.S. Anesthesia Partners Inc. of monopolizing the Texas anesthesia services market by purchasing most of the competing anesthesia practices in the state.

Expert Analysis

  • How AI Drafting Should Transform Patent Filing Strategies

    Author Photo

    As agentic artificial intelligence reduces the time and expense required to draft and file patents, companies should shift focus away from rationing drafting hours and more toward governing optionality, says Ian Schick at Paximal.

  • 5 Advertising Law Trends That Will Shape 2026

    Author Photo

    The legal landscape for advertisers will grow only more complex this year, with ongoing trends including a federal regulatory retreat, more aggressive action by the states, a focus on child privacy and expanded scrutiny of "natural" claims, say attorneys at Reed Smith.

  • Cannabis Industry Faces An Inflection Point This Year

    Author Photo

    Cannabis industry developments last year — from the passage of a new wholesale tax in Michigan, to an executive order accelerating the federal rescheduling process — presage a more mature phase of legalization this year, with hardening expectations and enforcement to come, says Alex Leonowicz at Howard & Howard.

  • Series

    Fly-Fishing Makes Me A Better Lawyer

    Author Photo

    Much like skilled attorneys, the best anglers prize preparation, presentation and patience while respecting their adversaries — both human and trout, says Rob Braverman at Braverman Greenspun.

  • 4 Ways GCs Can Manage Growing Service Of Process Volume

    Author Photo

    As automation and arbitration increase the volume of legal filings, in-house counsel must build scalable service of process systems that strengthen corporate governance and manage risk in real time, says Paul Mathews at Corporation Service Co.

  • Series

    The Law Firm Merger Diaries: Forming Measurable Ties

    Author Photo

    Relationship-building should begin as early as possible in a law firm merger, as intentional pathways to bringing people together drive collaboration, positive client response, engagements and growth, says Amie Colby at Troutman.

  • AG Watch: Va. Insulin Price Probe Signals Rising Scrutiny

    Author Photo

    Virginia Attorney General Jason Miyares' recent investigation into insulin manufacturers and pharmacy benefit managers for allegedly colluding to artificially inflate insulin prices reflects a broader trend to leverage consumer protection authority in high-impact healthcare matters, and the upcoming leadership change is unlikely to diminish scrutiny in this area, says Chuck Slemp at Cozen O'Connor.

  • FDA's AI Deployment Brings New Potential And Risks

    Author Photo

    The U.S. Food and Drug Administration's recent announcement about making agentic artificial intelligence tools available to agency employees may portend accelerated regulatory timelines and lower costs for drug companies and consumers, but potential errors and biases will necessitate additional safeguards, says Angela Silva at Lewis Brisbois.

  • 3 Key Takeaways From Planned Rescheduling Of Cannabis

    Author Photo

    An executive order reviving cannabis rescheduling represents a monumental change for the industry and, while the substance will remain illegal at the federal level, introduces several benefits, including improving state-legal cannabis operators' tax treatment, lowering the industry's legal risk profile, and leaving state-regulated markets largely intact, say attorneys at Dentons.

  • 6 Issues That May Follow The 340B Rebate Pilot Challenge

    Author Photo

    Though the Health Resources and Services Administration withdrew a pending case to reconsider the controversial 340B rebate pilot program, a number of crucial considerations remain, including the likelihood of a rework and questions about what that rework might look like, say attorneys at Spencer Fane.

  • 5 E-Discovery Predictions For 2026 And Beyond

    Author Photo

    2026 will likely be shaped by issues ranging from artificial intelligence regulatory turbulence to potential evidence rule changes, and e-discovery professionals will need to understand how to effectively guide the responsible and defensible adoption of emerging tools, while also ensuring effective safeguards, say attorneys at Littler.

  • Streamlining Product Liability MDLs With AI And Rule 16.1

    Author Photo

    With newly effective Rule 16.1 of the Federal Rules of Civil Procedure providing enhanced guidance on multidistrict litigation and the sophistication of artificial intelligence continuing to advance, parties have the opportunity to better confront the significant data challenges presented by product liability MDLs, say attorneys at Hollingsworth.

  • Business Considerations Amid Hemp Product Policy Change

    Author Photo

    With the passage of a bill fundamentally narrowing the federal definition of "hemp," there are practical and business considerations that brands, manufacturers and other parties should heed over the next year, including operational strategies, evaluating contract and counterparty risk, and tax implications, say attorneys at Foley Hoag.

  • Series

    Judges On AI: How Courts Can Boost Access To Justice

    Author Photo

    Arizona Court of Appeals Judge Samuel A. Thumma writes that generative artificial intelligence tools offer a profound opportunity to enhance access to justice and engender public confidence in courts’ use of technology, and judges can seize this opportunity in five key ways.

  • Fed. Circ. In November: Looking For Patent 'Blaze Marks'

    Author Photo

    The Federal Circuit's recent decision in Duke v. Sandoz serves as a warning that when patentees craft claims, they must provide adequate "blaze marks" that direct a skilled artisan to the specific claimed invention, and not just the individual claimed elements in isolation, say attorneys at Knobbe Martens.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.